Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi ...

"All healthcare providers should be aware of the risks of DPD deficiency," inform patients of toxicity risks, and test patients unless treatment is immediately needed, the agency said.

This year, the firm will focus on commercializing and further developing the ovarian cancer drug and discuss the registrational path with the FDA for a KRAS G12D inhibitor.

The company has garnered FDA fast-track status and will soon start a controlled trial of its oncolytic virus with standard therapy.

Wave is expecting feedback from US regulators on a path forward for WVE-006 as a potential alpha-1 antitrypsin deficiency therapy in mid-2026.

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

It will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...